Julius Few, MD The approach: How to support GLP-1 patients Patients dont just want answers
Our providers will guide you towards the right plan for you based on your medical history, lab work, and your objectives
This has been long in our treatment toolbox
Liraglutide has been shown to exhibit antioxidant and anti-inflammatory properties that reduce eNOS uncoupling and increase NO bioavailability, NO bioavailability is thereby maintained, endothelium-mediated vasorelaxation is preserved, and vascular remodeling and fibrosis are prevented
Retatrutide has no cardiovascular outcomes data yet
[1] [2] These medicines include semaglutide (Ozempic, Wegovy, Rybelsus), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and exenatide (Byetta, Bydureon), among others